Examining blood characteristics in Polycythemia Vera and secondary erythrocytosis
Study of Hematocrit to Hemoglobin Ratio and Red Blood Cell Distribution Width in Polycythemia Vera and Secondary Erythrocytosis
This study looks at blood characteristics in people with Polycythemia Vera and those with secondary erythrocytosis to see how they differ and what that means for their health.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Sohag University Academic / other |
| Locations | 1 site (Sohag) |
| Trial ID | NCT05993065 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze the hematocrit to hemoglobin ratio and red blood cell distribution width in patients diagnosed with Polycythemia Vera (PV) and those with secondary erythrocytosis. Data will be collected from patients at Sohag University Hospital, focusing on clinical manifestations, thrombosis history, and various blood parameters, including JAK2 mutation status. The study will include newly diagnosed PV patients and use secondary erythrocytosis patients as controls to better understand the differences in these conditions.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have been newly diagnosed with Polycythemia Vera.
Not a fit: Patients with chronic or acute myeloid leukemia or other myeloid neoplasms will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of Polycythemia Vera and improve diagnostic and treatment strategies for patients.
How similar studies have performed: While there have been studies on Polycythemia Vera, this specific approach focusing on the hematocrit to hemoglobin ratio and RDW is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients aged 18 years and older who were newly diagnosed to have polycythemia vera between September 2014 and November 2022 at Sohag university hospital, department of internal medicine, hematology unit and hematology outpatient clinic. Exclusion Criteria: * Patients were excluded if: (1) their disease was not newly diagnosed, (2) their disease met WHO criteria for chronic, acute myeloid leukemia or other myeloid neoplasms.
Where this trial is running
Sohag
- Faculty of Medicine — Sohag, Egypt (Recruiting)
Study contacts
- Principal investigator: Mahmoud Gaber — Sohag University
- Study coordinator: Mahmoud Gaber
- Email: mahmoudgaber@med.sohag.edu.eg
- Phone: +201007399833
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.